Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov 6;95(9):1174-9.
doi: 10.1038/sj.bjc.6603412. Epub 2006 Oct 3.

(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response

C M Gillham  1 , J A Lucey, M Keogan, G J Duffy, V Malik, A A Raouf, K O'byrne, D Hollywood, C Muldoon, J V Reynolds
Affiliations

(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response

C M Gillham et al. Br J Cancer. .

Abstract

To determine whether [(18)F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) could predict the pathological response in oesophageal cancer after only the first week of neoadjuvant chemoradiation. Thirty-two patients with localised oesophageal cancer had a pretreatment PET scan and a repeat after the first week of chemoradiation. The change in mean maximum standardised uptake value (SUV) and volume of metabolically active tissue (MTV) was compared with the tumour regression grade (TRG) in the final histology. Those who achieved a TRG of 1 and 2 were deemed responders and 3-5 nonresponders. In the responders (28%), the SUV fell from 12.6 (+/-6.3) to 8.1 (+/-2.9) after 1 week of chemoradiation (P=0.070). In nonresponders (72%), the results were 9.7 (+/-5.4) and 7.1 (+/-3.8), respectively (P=0.003). The MTV in responders fell from 36.6 (+/-22.7) to 22.3 (+/-10.4) cm(3) (P=0.180), while in nonresponders, this fell from 35.9 (+/-36.7) to 31.9 (+/-52.7) cm(3) (P=0.405). There were no significant differences between responders and nonresponders. The hypothesis that early repeat FDG-PET scanning may predict histomorphologic response was not proven. This may reflect an inflammatory effect of radiation that obscures tumour-specific metabolic changes at this time. This assessment may have limited application in predicting response to multimodal regimens for oesophageal cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage change in mean maximum SUV from pre- to during CRT relative to differing pathological response groups. TRG, tumour regression grade.
Figure 2
Figure 2
Percentage MTV from pre- to during CRT relative to differing pathological response groups. TRG, tumour regression grade.
See this image and copyright information in PMC

References

    1. Altorki N, Kent M, Ferrara RN, Port J (2002) Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 236: 177–183 - PMC - PubMed
    1. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A (2001) Only pathologic complete response neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized. Controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91: 2165–2174 - PubMed
    1. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA (2002) Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imag Biol 4: 301–310 - PubMed
    1. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337: 161–167 - PubMed
    1. Brink I, Hentschel M, Bley TA, Walch A, Mix M, Kleimaier M, Moser E, Imdahl A (2004) Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 30: 544–550 - PubMed

Substances